Literature DB >> 27890176

The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.

Eamonn S Molloy1, Cassandra M Calabrese2, Leonard H Calabrese2.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare, typically fatal, demyelinating central nervous system infection caused by reactivation of the John Cunningham virus that generally occurs in immunosuppressed patients. With an evolving understanding of a greater clinical heterogeneity of PML and significant implications for therapy, PML should be considered in the differential diagnosis of neurologic presentations of rheumatic diseases. Increased awareness of PML among rheumatologists is required, as earlier diagnosis and restoration of immune function may improve the otherwise grim prognosis associated with PML. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmune rheumatic diseases; Biologic therapy; Progressive multifocal leukoencephalopathy; Rituximab; Synthetic immunosuppressive therapy; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2017        PMID: 27890176     DOI: 10.1016/j.rdc.2016.09.009

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  5 in total

Review 1.  Neuro-ophthalmic side effects of molecularly targeted cancer drugs.

Authors:  M T Bhatti; A K S Salama
Journal:  Eye (Lond)       Date:  2017-10-20       Impact factor: 3.775

2.  Complications of Immunosuppression in Glomerular Disease.

Authors:  J Ashley Jefferson
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-24       Impact factor: 8.237

3.  A case of recurrent progressive multifocal leukoencephalopathy after human stem cell transplant, with detection of John Cunningham virus and human herpesvirus 6 on cerebrospinal fluid, treated with Mirtazapine, Olanzapine and Foscarnet.

Authors:  Matteo Pasca; Antonella Picchioni; Salvatore Mazzeo; Federica Terenzi; Elio Prestipino; Roberto Fratangelo; Anna Maria Repice; Giovanna Carlucci; Luca Massacesi; Alessandro Barilaro
Journal:  Intractable Rare Dis Res       Date:  2019-11

Review 4.  Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy.

Authors:  Maurizio Salvadori; Aris Tsalouchos
Journal:  World J Nephrol       Date:  2018-05-06

Review 5.  Avoidance of Harm From Treatment for ANCA-Associated Vasculitis.

Authors:  Catherine King; Lorraine Harper
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-11-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.